BIOMAT Database Logo BIOMAT Database Logo

[Comparison of the effectiveness of Cyclophosphamide and Cytembena in controlled clinical trial in nephrotic syndrome and chronic glomerulonephritis]. 1976

M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna

UI MeSH Term Description Entries
D009404 Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000179 Acrylates Derivatives of acrylic acid (the structural formula CH2

Related Publications

M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[A controlled clinical trial of Consupren versus cyclophosphamide in chronic glomerulonephritis].
February 1997, Casopis lekaru ceskych,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Primary chronic glomerulonephritis with nephrotic syndrome. Treatment with prednisone and cyclophosphamide].
December 1993, Vnitrni lekarstvi,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
January 1998, Terapevticheskii arkhiv,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Therapeutic effect of cyclophosphamide in patients with chronic glomerulonephritis with nephrotic syndrome].
January 2002, Terapevticheskii arkhiv,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Cyclophosphamide efficacy in maintenance therapy of nephrotic syndrome in patients with chronic glomerulonephritis].
January 2004, Terapevticheskii arkhiv,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Nephrotic syndrome in chronic intracapillary glomerulonephritis].
August 1951, Helvetica paediatrica acta,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood.
September 1970, Lancet (London, England),
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis.
December 1976, Canadian Medical Association journal,
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Nephrotic syndrome in chronic glomerulonephritis and tonsillectomy].
December 1971, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M Sasinka, and I Plenta, and E Kaiserová, and V Izakovic, and M Pavlovic, and CYTEMBENA/*THER USE, and I Slugen, and M Lehký, and J Stubna
[Chronic glomerulonephritis with nephrotic syndrome in children].
February 1974, Pediatriia,
Copied contents to your clipboard!